AU736697B2 - Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms - Google Patents

Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms Download PDF

Info

Publication number
AU736697B2
AU736697B2 AU56684/98A AU5668498A AU736697B2 AU 736697 B2 AU736697 B2 AU 736697B2 AU 56684/98 A AU56684/98 A AU 56684/98A AU 5668498 A AU5668498 A AU 5668498A AU 736697 B2 AU736697 B2 AU 736697B2
Authority
AU
Australia
Prior art keywords
ethyl
naphthyl
trifluoromethylphenyl
mixture
tetrahydropyridine hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU56684/98A
Other languages
English (en)
Other versions
AU5668498A (en
Inventor
Antoine Caron
Bruno Franc
Olivier Monnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU5668498A publication Critical patent/AU5668498A/en
Assigned to SANOFI-SYNTHELABO reassignment SANOFI-SYNTHELABO Amend patent request/document other than specification (104) Assignors: SANOFI
Application granted granted Critical
Publication of AU736697B2 publication Critical patent/AU736697B2/en
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS Request to Amend Deed and Register Assignors: SANOFI-SYNTHELABO
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU56684/98A 1996-12-23 1997-12-23 Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms Ceased AU736697B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR96/15904 1996-12-23
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
PCT/FR1997/002393 WO1998028271A1 (fr) 1996-12-23 1997-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (2)

Publication Number Publication Date
AU5668498A AU5668498A (en) 1998-07-17
AU736697B2 true AU736697B2 (en) 2001-08-02

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56684/98A Ceased AU736697B2 (en) 1996-12-23 1997-12-23 Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms

Country Status (38)

Country Link
EP (1) EP0950050B1 (en:Method)
JP (2) JP4499188B2 (en:Method)
KR (1) KR100586670B1 (en:Method)
CN (1) CN1129580C (en:Method)
AR (1) AR009672A1 (en:Method)
AT (1) ATE307802T1 (en:Method)
AU (1) AU736697B2 (en:Method)
BR (1) BR9714081A (en:Method)
CA (1) CA2275596C (en:Method)
CO (1) CO5070688A1 (en:Method)
CZ (1) CZ296689B6 (en:Method)
DE (1) DE69734460T2 (en:Method)
DK (1) DK0950050T3 (en:Method)
DZ (1) DZ2383A1 (en:Method)
EE (1) EE04188B1 (en:Method)
EG (1) EG21567A (en:Method)
ES (1) ES2251038T3 (en:Method)
FR (1) FR2757543B1 (en:Method)
HR (1) HRP970699B1 (en:Method)
HU (1) HU227425B1 (en:Method)
IL (1) IL129938A (en:Method)
IN (1) IN186976B (en:Method)
IS (1) IS2357B (en:Method)
MY (1) MY118015A (en:Method)
NO (1) NO312364B1 (en:Method)
NZ (1) NZ336130A (en:Method)
PL (1) PL190494B1 (en:Method)
RS (1) RS49882B (en:Method)
RU (1) RU2192416C2 (en:Method)
SA (1) SA98180971B1 (en:Method)
SI (1) SI0950050T1 (en:Method)
SK (1) SK285088B6 (en:Method)
TR (1) TR199901363T2 (en:Method)
TW (1) TW518322B (en:Method)
UA (1) UA60324C2 (en:Method)
UY (1) UY24825A1 (en:Method)
WO (1) WO1998028271A1 (en:Method)
ZA (1) ZA9711576B (en:Method)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
JP5504334B2 (ja) 2010-03-12 2014-05-28 株式会社日本触媒 吸水性樹脂の製造方法
EP2643294B1 (en) * 2011-04-15 2016-08-24 Emcure Pharmaceuticals Limited An improved rilpivirine process

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101381A1 (fr) * 1982-08-16 1984-02-22 Sanofi S.A. Trifluorométhylphényltétrahydropyridines à activité anorexigène, un procédé de préparation et compositions pharmaceutiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101381A1 (fr) * 1982-08-16 1984-02-22 Sanofi S.A. Trifluorométhylphényltétrahydropyridines à activité anorexigène, un procédé de préparation et compositions pharmaceutiques

Also Published As

Publication number Publication date
SK82899A3 (en) 1999-12-10
RS49882B (sr) 2008-08-07
UA60324C2 (uk) 2003-10-15
FR2757543A1 (fr) 1998-06-26
KR100586670B1 (ko) 2006-06-07
WO1998028271A1 (fr) 1998-07-02
EE04188B1 (et) 2003-12-15
FR2757543B1 (fr) 1999-04-02
UY24825A1 (es) 1998-04-21
ES2251038T3 (es) 2006-04-16
TR199901363T2 (xx) 1999-08-23
EE9900264A (et) 2000-02-15
SK285088B6 (sk) 2006-06-01
JP2009197022A (ja) 2009-09-03
NO993076D0 (no) 1999-06-22
MY118015A (en) 2004-08-30
IL129938A (en) 2004-06-20
TW518322B (en) 2003-01-21
JP2001507012A (ja) 2001-05-29
HU227425B1 (en) 2011-05-30
JP4499188B2 (ja) 2010-07-07
AR009672A1 (es) 2000-04-26
ATE307802T1 (de) 2005-11-15
SI0950050T1 (sl) 2006-04-30
IL129938A0 (en) 2000-02-29
NO312364B1 (no) 2002-04-29
CA2275596A1 (en) 1998-07-02
YU28999A (sh) 2003-01-31
CN1129580C (zh) 2003-12-03
IS5076A (is) 1999-06-10
IS2357B (is) 2008-04-15
CA2275596C (en) 2005-10-11
NO993076L (no) 1999-06-22
NZ336130A (en) 2001-01-26
SA98180971B1 (ar) 2006-09-13
KR20000069504A (ko) 2000-11-25
HRP970699A2 (en) 1998-10-31
CO5070688A1 (es) 2001-08-28
DZ2383A1 (fr) 2002-12-28
EP0950050B1 (fr) 2005-10-26
PL190494B1 (pl) 2005-12-30
HUP0001387A2 (hu) 2000-09-28
DE69734460T2 (de) 2006-07-06
HK1024002A1 (en) 2000-09-29
BR9714081A (pt) 2000-05-09
ZA9711576B (en) 1998-06-25
DE69734460D1 (de) 2005-12-01
CZ296689B6 (cs) 2006-05-17
EP0950050A1 (fr) 1999-10-20
EG21567A (en) 2001-12-31
DK0950050T3 (da) 2006-01-23
HUP0001387A3 (en) 2002-03-28
CN1241180A (zh) 2000-01-12
PL334256A1 (en) 2000-02-14
AU5668498A (en) 1998-07-17
CZ229299A3 (cs) 1999-09-15
IN186976B (en:Method) 2001-12-22
HRP970699B1 (en) 2007-03-31
RU2192416C2 (ru) 2002-11-10

Similar Documents

Publication Publication Date Title
JP2009102345A (ja) 結晶性ジベンゾチアゼピン誘導体およびその抗精神病薬としての使用
WO2011050962A1 (en) Acid addition salts of lenalidomide
MXPA00002956A (es) Composiciones orales de levosimendan.
CA2275596C (en) Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms
JP2002532470A (ja) パロキセチンマレイン酸塩の製法
US6489334B2 (en) Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms
JP2002511466A (ja) マレイン酸パロキセチン
JPH05229945A (ja) 特定の結晶変態を有する１，４−ジヒドロ−２，６−ジメチル−４−（３−ニトロフエニル）−３，５−ピリジンジカルボン酸イソプロピル−（２−メトキシエチル）を含有する薬学的調製物
JP2009280581A (ja) テトラヒドロピリジン誘導体の微粒子形態
MXPA99005620A (en) Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms
MXPA06006731A (es) Forma polimorfica de dexcetoprofeno trometamol, su preparacion y composiciones que lo contienen.
HU210879A9 (en) Pharmaceutical agents
EP1858847A1 (en) Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions
MXPA00009884A (en) Paroxetine maleate
AU3618699A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA00010435A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA99005621A (en) Micro-particulate form of a tetrahydropyridin derivative
CZ20003722A3 (cs) Maleat paroxetinu
MXPA98001705A (en) Form of alternate glass of the tazofel
JPH11514978A (ja) タゾフェロンの既存のものに変わる結晶型
MXPA98006498A (en) Progestagenos cristali

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: SANOFI-SYNTHELABO

Free format text: FORMER NAME: SANOFI

FGA Letters patent sealed or granted (standard patent)